Durect corporation announces positive results from trial of dur-928 in alcoholic hepatitis patients

Durect corporation announces positive results from the phase 2a clinical trial of dur-928 in alcoholic hepatitis patients in a late-breaking presentation at the liver meeting®.durect corp - all patients treated with dur-928 in trial survived 28-day follow-up period.durect corp - dur-928 was well tolerated at all doses tested.durect corp - there were no drug-related serious adverse events on dur-928 trial.durect corp - patients treated with dur-928 had a statistically significant reduction from baseline in bilirubin at day 7 and 28 and meld at day 28.durect corp - lille scores were statistically significantly lower than those from a well-matched group of patients in a contemporary ongoing trial.
DRRX Ratings Summary
DRRX Quant Ranking